Metaboliczne aspekty działania leków beta-adrenolitycznych – (część II) Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2010
Słowa kluczowe:
leki β-adrenolityczne, aktualna pozycja wśród leków kardiologicznych
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leki β-adrenolityczne są niejednorodną grupą leków, o bardzo szerokich wskazaniach i licznych przeciwwskazaniach. Niemniej, bez tej grupy leków nie sposób wyobrazić sobie dzisiaj farmakoterapię chorób sercowo-naczyniowych. Poza klasycznymi wskazaniami, takimi jak: choroba niedokrwienna serca i zawał serca, nadciśnienie tętnicze, przewlekła niewydolność serca i zaburzenia rytmu, nowoczesne β-adrenolityki mają je rozszerzone o cukrzycę, zaburzenia lipidowe i niewydolność nerek. Autorzy artykułu podsumowują aktualną wiedzę o tej fascynującej grupie leków.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Światowiec , A., & Kuch , M. (2010). Metaboliczne aspekty działania leków beta-adrenolitycznych – (część II) . Medycyna Faktów , 3(2(7), 35-40. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2602
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bristow M.R., Port J.D., Kelly R.A.: Treatment of heart failure: pharmacologic methods. W: Heart Disease: A Textbook of Cardiovascular Medicine, sixth edition Braunwald E., Zippes D.P., Libby P. (red.). W.B. Saunders Company, Philadelphia 2001: 562-599.
2. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998; 339: 1759-1765.
3. Dickstein K., Cohen-Solal A., Filippatos G. et al. Wytyczne 2008 Europejskiego Towarzystwa Kardiologicznego dotyczące rozpoznawania i leczenia ostrej oraz przewlekłej niewydolności serca. Kardiologia Polska 2008; 66 suplement IV, 389-454.
4. Hunt S.A., Abraham W.T., Chin M.H. et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: 154-235.
5. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-62.
6. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002; 106: 394-398.
7. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N. Engl. J. Med. 1998; 339; 489-497.
8. Norwegian Timolol Trial Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981; 304: 801-807.
9. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
10. BHAT Research group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982; 247: 1707-1714.
11. The Miami Research Group: Metoprolol in acute myocardial infarction – randomized placebo-controlled trial. Eur. Heart J. 1985; 6: 199-226.
12. ISIS-1 Collaborative Group: Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57-66.
13. Roberts R., Rogers W.J., Mueller H.S. et al.: Immediate versus differed beta blockade following thrombolytic therapy in patients with acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI IIB). Circulation 1991; 83: 422-437.
14. Yusuf S., Lessen J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J. Hypertens. 1993; 11(suppl. 4): S61-S73.
15. Freemantle N., Cleland J., Young P. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 26: 1730-1737.
16. Beta-Blocker Pooling Project Research Group: Subgroup findings from randomised trials in post-myocardial infarction patients. Eur. Heart J. 1988; 9: 8-16.
17. Bertrand M.E., Simoons M.L., Fox K.A. et al.; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persi stent ST-segment elevation. Eur. Heart J. 2002; 23: 1809-1840.
18. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic. Cardiol. 2002; 5: 215-223.
19. Rauls R.A., Tan Y., Knuepfer M.M.: Central beta-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005; 1048: 98-107.
20. Hedblad B., Wikstrand J., Janzon L. et al.: Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726.
21. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.
22. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007; 147: 10-18.
23. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
24. Dunn C.J., Lea A.P., Wagstaff H.: Carvedilol. A Reappraisal of its Phramacological Properties and Therapeutic Use in Cardiovascular Disorders. Drugs 1997; 54: 161-185.
25. Ohtsuka T., Hamada M., Saeki H. et al.: Serum levels of matrix metalloproteinases and tumor necrosis factor in patients with idiopathic dilated cardiomyopathy and effects of carvedilol on these levels. Am. J. Cardiol. 2002; 91: 1024-1027.
26. Rossig L., Haendeler J., Mallat Z. et al.: Congestive heart failure induces cell apoptosis: protective role of carvedilol. JACC 2000; 36: 2081-2089.
27. Mayer B., Holmer S.R., Hengstenberg C. et al.: Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int. J. Cardiol. 2005; 103: 182-6.
28. Matsumura T., Tsushima K., Ohtaki E. et al.: Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J. Cardiol. 2002; 39: 253-7.
29. Yuan Z., Shioji K., Kihara Y. et al.: Cardioprotective effects of carvedilol on acute autoimmune myocarditis anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H83-H90.
30. Falciani M., Rinaldi B., D’Agostino B. et al.: Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001; 38: 922-929.
31. Vyssoulis G.P., Marinakis A.G., Aznaouridis K.A. et al.: The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am. J. Hypertens. 2004; 17: 582-9.
32. Chłopicki S., Kozlovski V.I., Gryglewski R.J.J.: NO-dependent vasodilatation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5HT-1A receptors. Physiol. Pharmacol. 2002; 53: 615-624.
33. Mollnau H., Schulz E., Daiber A. et al.: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 615-621.
34. Ignarro L.J.: Experimental evidences of nitric oxide-dependent vasodilatatory activity of nebivolol, a third generation beta-blocker. Blood Pressure 2004; 13(S1): 3-17.
35. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C.: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000; 36: 3401-3403.
36. Nakamura K., Kusano K., Nakamura Y. et al.: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-71.
37. Feuerstein G.Z., Yue T.L.: A potent antioxidant, SB 209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994; 48: 385-391.
38. Lopez B.L., Christopher T.A., Yue T.L. et al.: Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radicalinduced endothelial dysfunction. Pharmacology 1995; 51: 165-73.
39. De Grott A.A., Mathy M.J., van Zwieten P.A. et al.: Antioxidant activity of nebivolol in the rat aorta. J. Cardiovasc. Pharmacol. 2004; 43: 148-153.
40. van Os J.S., van Brummelen P., Woittiez A.J.J.: Betaxolol in obese hypertensive patients. Long-term effects on blood pressure and serum lipids. Neth. J. Med. 1992; 40: 227-231.
41. Bakris G.L., Fonseca V., Kathol R.E. et al.: for the GEMINI investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004; 292: 2227-2236.
42. Malmeberg K.: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI study group. Br. Med. J. 1997; 314: 1512-1515.
43. Mc Donald C., Majumdar S., Mahon L.J., Johnson J.: The effectiveness of beta-blockers after myocardial infarction in patients with type 2 diabetes. Diabetes Care 2005; 28: 2113-2117.
44. Deedwania P.C.: Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol. Clin. 2005; 23: 139-152.
45. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Int. Med. 2003; 138: 917-924.
46. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
2. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998; 339: 1759-1765.
3. Dickstein K., Cohen-Solal A., Filippatos G. et al. Wytyczne 2008 Europejskiego Towarzystwa Kardiologicznego dotyczące rozpoznawania i leczenia ostrej oraz przewlekłej niewydolności serca. Kardiologia Polska 2008; 66 suplement IV, 389-454.
4. Hunt S.A., Abraham W.T., Chin M.H. et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: 154-235.
5. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-62.
6. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002; 106: 394-398.
7. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N. Engl. J. Med. 1998; 339; 489-497.
8. Norwegian Timolol Trial Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981; 304: 801-807.
9. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
10. BHAT Research group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982; 247: 1707-1714.
11. The Miami Research Group: Metoprolol in acute myocardial infarction – randomized placebo-controlled trial. Eur. Heart J. 1985; 6: 199-226.
12. ISIS-1 Collaborative Group: Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57-66.
13. Roberts R., Rogers W.J., Mueller H.S. et al.: Immediate versus differed beta blockade following thrombolytic therapy in patients with acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI IIB). Circulation 1991; 83: 422-437.
14. Yusuf S., Lessen J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J. Hypertens. 1993; 11(suppl. 4): S61-S73.
15. Freemantle N., Cleland J., Young P. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 26: 1730-1737.
16. Beta-Blocker Pooling Project Research Group: Subgroup findings from randomised trials in post-myocardial infarction patients. Eur. Heart J. 1988; 9: 8-16.
17. Bertrand M.E., Simoons M.L., Fox K.A. et al.; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persi stent ST-segment elevation. Eur. Heart J. 2002; 23: 1809-1840.
18. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic. Cardiol. 2002; 5: 215-223.
19. Rauls R.A., Tan Y., Knuepfer M.M.: Central beta-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005; 1048: 98-107.
20. Hedblad B., Wikstrand J., Janzon L. et al.: Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726.
21. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.
22. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007; 147: 10-18.
23. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
24. Dunn C.J., Lea A.P., Wagstaff H.: Carvedilol. A Reappraisal of its Phramacological Properties and Therapeutic Use in Cardiovascular Disorders. Drugs 1997; 54: 161-185.
25. Ohtsuka T., Hamada M., Saeki H. et al.: Serum levels of matrix metalloproteinases and tumor necrosis factor in patients with idiopathic dilated cardiomyopathy and effects of carvedilol on these levels. Am. J. Cardiol. 2002; 91: 1024-1027.
26. Rossig L., Haendeler J., Mallat Z. et al.: Congestive heart failure induces cell apoptosis: protective role of carvedilol. JACC 2000; 36: 2081-2089.
27. Mayer B., Holmer S.R., Hengstenberg C. et al.: Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int. J. Cardiol. 2005; 103: 182-6.
28. Matsumura T., Tsushima K., Ohtaki E. et al.: Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J. Cardiol. 2002; 39: 253-7.
29. Yuan Z., Shioji K., Kihara Y. et al.: Cardioprotective effects of carvedilol on acute autoimmune myocarditis anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H83-H90.
30. Falciani M., Rinaldi B., D’Agostino B. et al.: Effects of nebivolol on human platelet aggregation. J. Cardiovasc. Pharmacol. 2001; 38: 922-929.
31. Vyssoulis G.P., Marinakis A.G., Aznaouridis K.A. et al.: The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am. J. Hypertens. 2004; 17: 582-9.
32. Chłopicki S., Kozlovski V.I., Gryglewski R.J.J.: NO-dependent vasodilatation induced by nebivolol in coronary circulation is not mediated by beta-adrenoreceptors or by 5HT-1A receptors. Physiol. Pharmacol. 2002; 53: 615-624.
33. Mollnau H., Schulz E., Daiber A. et al.: Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 615-621.
34. Ignarro L.J.: Experimental evidences of nitric oxide-dependent vasodilatatory activity of nebivolol, a third generation beta-blocker. Blood Pressure 2004; 13(S1): 3-17.
35. Brehm B.R., Bertsch D., von Fallois J., Wolf S.C.: Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J. Cardiovasc. Pharmacol. 2000; 36: 3401-3403.
36. Nakamura K., Kusano K., Nakamura Y. et al.: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105: 2867-71.
37. Feuerstein G.Z., Yue T.L.: A potent antioxidant, SB 209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994; 48: 385-391.
38. Lopez B.L., Christopher T.A., Yue T.L. et al.: Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radicalinduced endothelial dysfunction. Pharmacology 1995; 51: 165-73.
39. De Grott A.A., Mathy M.J., van Zwieten P.A. et al.: Antioxidant activity of nebivolol in the rat aorta. J. Cardiovasc. Pharmacol. 2004; 43: 148-153.
40. van Os J.S., van Brummelen P., Woittiez A.J.J.: Betaxolol in obese hypertensive patients. Long-term effects on blood pressure and serum lipids. Neth. J. Med. 1992; 40: 227-231.
41. Bakris G.L., Fonseca V., Kathol R.E. et al.: for the GEMINI investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA 2004; 292: 2227-2236.
42. Malmeberg K.: Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI study group. Br. Med. J. 1997; 314: 1512-1515.
43. Mc Donald C., Majumdar S., Mahon L.J., Johnson J.: The effectiveness of beta-blockers after myocardial infarction in patients with type 2 diabetes. Diabetes Care 2005; 28: 2113-2117.
44. Deedwania P.C.: Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol. Clin. 2005; 23: 139-152.
45. Shlipak M.G.: Pharmacotherapy for heart failure in patients with renal insufficiency. Ann. Int. Med. 2003; 138: 917-924.
46. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.